112 articles with Blueprint Medicines
Blueprint Medicines Corporation announced that, effective on September 1, 2020, the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 15,236 shares of its common stock and an aggregate of 7,617 restricted stock units to five new employees under Blueprint Medicines' 2020 Inducement Plan.
These prices refer to the company’s list price. Most patients will not pay that price because of various forms of health insurance or patient assistance programs.
Although January was a fairly slow month for PDUFA dates for the U.S. Food and Drug Administration, February has a stronger schedule.
Blueprint Medicines Presents Updated EXPLORER Trial Data for Avapritinib in Patients with Systemic Mastocytosis at 24th EHA Congress
Blueprint Medicines Corporation, announced updated data from the ongoing, registration-enabling EXPLORER trial of avapritinib in patients with systemic mastocytosis.
Blueprint Medicines Presents NAVIGATOR Trial Data in PDGFRA Exon 18 Mutant GIST and Fourth-Line GIST at ASCO 2019 Supporting Planned Marketing Applications for Avapritinib
Blueprint Medicines Corporation announced data from the registration-enabling NAVIGATOR trial of avapritinib in patients with PDGFRA Exon 18 mutant gastrointestinal stromal tumors and fourth-line GIST.
Blueprint Medicines Corporation announced its participation in the following upcoming investor conferences
Blueprint Medicines Announces Data Presentations at ASCO and EHA Meetings from Registration-Enabling Clinical Trials of Avapritinib and BLU-667 Across Multiple Patient Populations
Blueprint Medicines to Host Investor Event and Webcast at ASCO on Monday, June 3, 2019
Blueprint Medicines Corporation reported financial results and provided a business update for the quarter ended March 31, 2019.
Blueprint Medicines Corporation announced that Jeff Albers, Blueprint Medicines' Chief Executive Officer, will present a company overview at the Bank of America Merrill Lynch 2019 Health Care Conference on Wednesday, May 15, 2019 at 3:00 p.m. PT.
Blueprint Medicines Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares of Common Stock - April 2, 2019
Blueprint Medicines Corporation announced the closing of its previously announced underwritten public offering of 4,662,162 shares of its common stock at a public offering price of $74.00 per share, including the exercise in full by the underwriters of their option to purchase additional shares of common stock.
Blueprint Medicines Corporation announced the pricing of an underwritten public offering of 4,054,054 shares of its common stock at a public offering price of $74.00 per share, before underwriting discounts and commissions.
Blueprint Medicines Corporation, a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, announced that it has commenced an underwritten public offering of $300,000,000 in shares of its common stock.
Blueprint Medicines Corporation announced that Jeff Albers, Blueprint Medicines' Chief Executive Officer, will present a company overview at the 39th Annual Cowen & Co. Health Care Conference on Tuesday, March 12, 2019 at 8:40 a.m. ET.
Blueprint Medicines Corporation reported financial results and provided a business update for the fourth quarter and full year ended December 31, 2018.
Blueprint Medicines to Report Fourth Quarter and Full Year 2018 Financial Results on Tuesday, February 26, 2019
Blueprint Medicines Corporation announced that it will host a live conference call and webcast at 8:30 a.m. ET on Tuesday, February 26, 2019 to report its fourth quarter and full year 2018 financial results and provide a corporate update.
Blueprint Medicines Announces "2020 Blueprint" Global Business Strategy and Outlines Key Corporate Goals
Top-line avapritinib data support planned NDA for PDGFRA Exon 18 mutant GIST and fourth-line GIST in first half 2019
Blueprint Medicines Presents Foundational Preclinical Data Supporting the Development of BLU-782, a Highly Selective ALK2 Inhibitor, for the Treatment of Patients with Fibrodysplasia Ossificans Progressiva
Plan to Initiate Phase 1 Clinical Trial in Healthy Volunteers in First Quarter of 2019
This week, the Business Journals compiled a list of the 25 companies across the United States with the highest median salary for employees. According to the list, median salaries for these companies ranked from $198,000 to $495,000. Of those companies listed, more than half were in the pharma or ...
Blueprint Medicines Company Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares of Common Stock
Goldman Sachs & Co. LLC, Morgan Stanley and Cowen acted as joint book-running managers for the offering.
Thermo Fisher Scientific Signs Oncology Companion Diagnostic Development Agreement With Blueprint Medicines
Thermo Fisher Scientific announced today it has expanded the development of its Oncomine Dx Target Test as a CDx for BLU-667 by entering into an agreement with Blueprint Medicines.